Skip to main content

Table 1 Determination of the urinary tract functioning status and pretreatment eGFR of the 244 patients who underwent cisplatin-based chemotherapies

From: A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study

  Pretreatment eGFR
≥60 mL/min/1.73m2
Pretreatment eGFR
< 60 mL/min/1.73m2
Bilateral
functioning
kidneys
(n = 83)
Solitary
functioning
kidney
(n = 36)
Bilateral
functioning
kidneys
(n = 45)
Solitary
functioning
kidney
(n = 80)
Bilateral functoinal kidneys status
 BC with bilateral intact kidneys 63 (75.9%) 23 (51.2%)
 BC with an unilateral nephrostomy 4 (4.8%) 9 (20.0%)
 UTUC without nephroureterectomy or hydronephrosis 11 (13.3%) 11 (24.4%)
 UTUC with an ipsilateral nephrostomy 2 (2.4%) 1 (2.2%)
 BC + UTUC without nephroureterectomy or hydronephrosis 3 (3.6%) 1 (2.2%)
Solitary functional kidney status
 UTUC after nephroureterectomy 7 (19.4%) 37 (46.4%)
 UTUC without nephroureterectomy with an ipsilateral 11 (30.5%) 22 (27.5%)
 UTUC in the solitary kidney without hydronephroisis 1 (2.7%) 2 (2.5%)
 UTUC in the solitary kidney with the ipsilateral nephrostomy 0 (0.0%) 1 (1.2%)
 BC with an unilateral hydroneohrosis 7 (19.4%) 5 (6.2%)
 BC with bilateral hydronephroses with unilateral nephrostomy 2 (5.6%) 8 (10.0%)
 BC with a solitary kidney 3 (8.4%) 1 (1.2%)
 BC + UTUC after an unilateral nephroureterectomy 3 (8.4%) 2 (2.5%)
 BC + UTUC with an unilateral hydronephrosis 2 (5.6%) 2 (2.5%)
  1. BC bladder cancer, UTUC upper urinary tract urothelial cancer
\